Allergan plc

Headquarters: Dublin, Ireland Sector: Healthcare Allergan is one of the best pharmaceutical stocks to buy in 2022 because it is expected to benefit from the ongoing demand for dermatological treatments. As people around the globe increasingly adopt a more Westernized lifestyle, the incidence of skin diseases such as eczema, psoriasis, and acne is also expected to rise. As the largest pure-play Botox manufacturer in the world, Allergan is likely to see demand for the product increase over the next few years as the aging population grows and a greater percentage of this group begins to seek out cosmetic procedures such as Botox. The company also has a robust pipeline of drugs in different stages of development. Its major pipeline candidates include Selinexor, which is in Phase III development for the treatment of metastatic squamous non-small cell lung cancer, and Selinexor, which is in Phase Iii Clinical trials for the treatment of metastatic colorectal cancer.

AstraZeneca plc

Headquarters: London, England Sector: Healthcare AstraZeneca is another great stock to buy in 2022 as it is focused on developing new therapies for serious diseases such as cancer, diabetes, heart conditions, and respiratory disorders. A number of the company’s pipeline candidates are expected to show up in the next few years, making it a good investment for short-term and long-term investors. AstraZeneca is currently working on a new therapy for multiple myeloma, a cancer that develops in bone marrow. It is also developing a treatment for non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease that can cause liver fibrosis and inflammation. AstraZeneca is also working on a therapy for psoriasis, a chronic skin condition that can lead to itchiness and scarring. The company recently completed the acquisition of Intercell, which gives it additional therapy candidates in the areas of infectious diseases and immunology.

Bristol-Myers Squibb Co.

Headquarters: New York, NY Sector: Healthcare Bristol-Myers Squibb is a great stock to buy in 2022 because of its focus on developing therapies for some of the world’s biggest diseases. The company has a robust pipeline of candidates in various stages of development, including immuno-oncology therapies, diabetes therapies, cardiovascular therapies, and hepatitis B treatments. BMS has a number of potential blockbuster candidates such as immuno-oncology therapies Opdivo and Yescarta, which are currently being evaluated in clinical trials for the treatment of various types of cancers. BMS is also developing a therapy for non-alcoholic steatohepatitis (NASH) with the goal of treating the underlying cause of the disease rather than just the symptoms. A major area of focus for BMS is diabetes, given the rising global prevalence of the disease. The company’s blockbuster drug, dulaglutide, is currently being evaluated in Phase Iii Clinical Trials for the treatment of type 2 diabetes.

Eli Lilly and Company

Headquarters: Indianapolis, IN Sector: Healthcare Lilly is a great stock to buy in 2022 given its commitment to both new product development and the acquisition of other pharmaceutical companies. Lilly has a robust pipeline of products in various stages of development, including solanezumab for the treatment of Alzheimer’s disease, galcanezumab for the treatment of pain in people with knee osteoarthritis, and taltz for the treatment of moderate to severe psoriasis. The company’s most promising candidate is ibalizumab, which is being evaluated in Phase III clinical trials for the treatment of people with moderate-to-severe idiopathic pulmonary fibrosis (IPF). Lilly is also actively pursuing deals to acquire other pharmaceutical companies. Its most notable acquisition so far has been the purchase of Cytokinetics, which focuses on the discovery, development, and commercialization of therapeutics addressing metabolic diseases.

F. Hoffmann-La Roche Ltd.

Headquarters: Basel, Switzerland Sector: Healthcare Roche is a great pharmaceutical stock to buy in 2022 because it has a robust pipeline of candidates across both oncology and immunology sectors. Roche’s most promising candidate is saracatinib, which is being evaluated in clinical trials for the treatment of non-small cell lung carcinoma (NSCLC). Roche is also developing a combination therapy for the treatment of NSCLC that combines the company’s investigational drug saracatinib with Genentech’s RTS-IVAL vaccine. Roche is also exploring new areas for growth through both internal development and acquisition. The company recently acquired Cytokinetics, which focuses on the discovery, development, and commercialization of therapeutics addressing metabolic diseases. The company’s Phase III clinical trial of an immunotherapy for the treatment of non-Hodgkin’s lymphoma is also progressing well and is expected to report top-line results in 2021.

Pfizer Inc.

Headquarters: New York, NY Sector: Healthcare Pfizer is another great stock to buy in 2022. The company recently pulled out of the deal to acquire Allergan, leaving it with plenty of money to fund its own pipeline of drugs in development and make more acquisitions. Pfizer’s investment in its own internal pipeline is likely to pay off in the near future, as the company is exploring a number of new indications for its blockbuster rheumatoid arthritis drug Xeljanz, including the treatment of non-alcoholic steatohepatitis (NASH). Pfizer is also exploring the use of Xeljanz for the treatment of idiopathic pulmonary fibrosis (IPF), a rare but serious lung disease. The company has already initiated Phase III clinical trials for Xeljanz in IPF, and the results should be available in the next few years.

Merck and Co., Inc.

Headquarters: Whitehouse Station, NJ Sector: Healthcare Merck is another great pharmaceutical stock to buy in 2022 as it is currently benefiting from the rising popularity of immunotherapies. The company’s immunotherapy Keytruda is currently approved for the treatment of a number of types of cancers, including NSCLC, melanoma, and kidney cancer. Merck’s most promising candidate is the investigational drug brilanib, which is being evaluated in Phase III clinical trials for the treatment of IPF. While the company’s near-term results might not be as spectacular as other pharmaceutical stocks, Merck is a great long-term investment that will likely outperform the market over the next decade.

Conclusion

The pharmaceutical industry is growing as the global population becomes more health-conscious and treatments for previously untreatable diseases are being discovered. All of the companies on this list are healthcare stocks with strong pipelines of new drugs in development that will have the potential to be blockbusters. Investors can benefit from investing in these companies now and holding the stocks for several years as they wait for the new drugs to be approved. If you’re looking to invest in the pharmaceutical sector but aren’t sure which stocks to buy right now, we have some great news for you. In this article, we’ll discuss some of the best pharma stocks to buy in 2022 and why they are a great investment opportunity right now.

The post Best Pharmaceuticals Stocks To Buy Now in 2022 appeared first on Best Stocks.